OBJECTIVES: To conduct a budget impact and cost effectiveness analysis of ferric carboxymaltose in Russian patients with colon cancer in preoperative period. METHODS: Based on literature data (Salvadora Delgado et al. 2013, Efficacy of Preoperative Administration of Ferric Carboxymaltose in Colon Cancer Patients and Anemia) we created a pharmacoeconomic model of intravenous iron therapy in patients with colon cancer and anemia. The study included two groups (100 patients each), treated with ferric carboxymaltose and placebo, respectively. The model included costs of medications, hospitalization and transfusions. RESULTS: Total costs were 10 679 174 rub. in placebo group and 10 518 707 rub. in ferric carboxymaltose group. The costs of blood transfusion were 3.9 times lower in carboxymaltose group compared to control (placebo group); hospitalization in this group lasted shorter, which reduced costs 1.23 times (4 155 000 rub. and 5 100 000 rub., respectively). The role of cost effectiveness ratio in terms of clinical result without clinical complications was 132 644,50  for ferric carboxymaltose and 145 294,90 in placebo group. CONCLUSIONS: The application of ferric carboxymaltose in patients with colon cancer is justified by the comparative effectiveness estimated in budget impact analysis, and allows reducing costs in healthcare system.